[go: up one dir, main page]

ATE505464T1 - Feste form von amg 706 und pharmazeutische zusammensetzungen davon - Google Patents

Feste form von amg 706 und pharmazeutische zusammensetzungen davon

Info

Publication number
ATE505464T1
ATE505464T1 AT06849937T AT06849937T ATE505464T1 AT E505464 T1 ATE505464 T1 AT E505464T1 AT 06849937 T AT06849937 T AT 06849937T AT 06849937 T AT06849937 T AT 06849937T AT E505464 T1 ATE505464 T1 AT E505464T1
Authority
AT
Austria
Prior art keywords
amg
amorphous
drug substance
crystallization inhibitor
pharmaceutical compositions
Prior art date
Application number
AT06849937T
Other languages
English (en)
Inventor
Belle B Liu
Gonzalo Alva
Nina Cauchon
Seshadri Neervannan
Pengzu Zhou
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE505464T1 publication Critical patent/ATE505464T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06849937T 2005-12-23 2006-12-08 Feste form von amg 706 und pharmazeutische zusammensetzungen davon ATE505464T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75390905P 2005-12-23 2005-12-23
US11/636,183 US20080108664A1 (en) 2005-12-23 2006-12-07 Solid-state form of AMG 706 and pharmaceutical compositions thereof
PCT/US2006/047238 WO2007087026A2 (en) 2005-12-23 2006-12-08 Solid-state form of amg 706 and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE505464T1 true ATE505464T1 (de) 2011-04-15

Family

ID=38198261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06849937T ATE505464T1 (de) 2005-12-23 2006-12-08 Feste form von amg 706 und pharmazeutische zusammensetzungen davon

Country Status (8)

Country Link
US (3) US20080108664A1 (de)
EP (1) EP2013198B1 (de)
JP (1) JP5830216B2 (de)
AT (1) ATE505464T1 (de)
AU (1) AU2006336563B2 (de)
CA (1) CA2633077C (de)
DE (1) DE602006021348D1 (de)
WO (1) WO2007087026A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101925436B1 (ko) 2008-04-10 2018-12-05 버지니아 커먼웰스 유니버시티 암 치료를 위한 종양 저 산소 상태의 유도
WO2009140549A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
US20100003319A1 (en) * 2008-07-02 2010-01-07 Glenmark Generics Ltd. Raloxifene immediate release tablets
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
CN102884194B (zh) 2010-03-11 2015-07-22 健康研究股份有限公司 含增强免疫应答的Fc融合蛋白的方法和组合物
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JP7581052B2 (ja) 2018-04-13 2024-11-12 サムヤン ホールディングス コーポレイション レナリドミドの経口用コーティング錠剤組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2762522B2 (ja) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 血管新生阻害剤
CA2011116C (en) 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
JPH02279769A (ja) * 1989-04-20 1990-11-15 Kao Corp ブリリアントカーミン６ｂナトリウム塩の無定形物、その製造法及びこれを含有する化粧料
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DK0828495T3 (da) * 1995-06-01 2003-02-24 Searle & Co Misoprostolholdige faste stabiliserede dispersioner
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6582921B2 (en) * 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO2000012089A1 (en) 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999045009A1 (en) 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
CA2336848A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
AU766081B2 (en) 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
DK1244647T3 (da) 1999-11-05 2006-09-25 Astrazeneca Ab Quinzolinderivater som VIGF-inhibitorer
EP1233943B1 (de) 1999-11-24 2011-06-29 Sugen, Inc. Ionisierbare indolinon derivate und deren verwendung als ptk liganden
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
PL372880A1 (en) 2002-03-15 2005-08-08 Pharmacia Corporation Crystalline parecoxib sodium
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases

Also Published As

Publication number Publication date
US20080108664A1 (en) 2008-05-08
AU2006336563A1 (en) 2007-08-02
US20130317227A1 (en) 2013-11-28
WO2007087026A9 (en) 2009-01-08
CA2633077C (en) 2012-02-21
WO2007087026A3 (en) 2007-09-13
EP2013198A2 (de) 2009-01-14
WO2007087026A2 (en) 2007-08-02
US20100331548A1 (en) 2010-12-30
EP2013198B1 (de) 2011-04-13
JP2009527460A (ja) 2009-07-30
CA2633077A1 (en) 2007-08-02
AU2006336563B2 (en) 2010-08-26
DE602006021348D1 (de) 2011-05-26
JP5830216B2 (ja) 2015-12-09
US8648199B2 (en) 2014-02-11

Similar Documents

Publication Publication Date Title
ATE505464T1 (de) Feste form von amg 706 und pharmazeutische zusammensetzungen davon
DK1150959T3 (da) Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighed
DE60118547D1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
CY1118179T1 (el) Φαρμακευτικη συνθεση
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
DE602006017965D1 (de) Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
MY128971A (en) Solid-state form of celecoxib having enhanced bioavailability
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP1844779A3 (de) Tergurid/Protergurid zur Behandlung von chronischen Schmerzen (z.B. Migräne)
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
JP2007119497A5 (de)
ATE489380T1 (de) Hydratformen von amg706
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
DE60236443D1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
CY1108846T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει αναστολεα ace και μεθοδος για την παρασκευη της
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties